Research advances of m6A modification in lung cancer
10.3760/cma.j.cn112434-20220323-00086
- VernacularTitle:m6A修饰在肺癌中的研究进展
- Author:
Qiu LI
1
;
Donghong CHEN
;
Jiashun CAO
Author Information
1. 清华大学附属北京清华长庚医院科研部 清华大学临床医学院，北京 102218
- From:
Chinese Journal of Thoracic and Cardiovascular Surgery
2022;38(10):634-640
- CountryChina
- Language:Chinese
-
Abstract:
The morbidity and mortality of lung cancer are always at the forefront of malignant tumors. To improve the therapeutic effects and overall survival of lung cancer patients is one of the key areas both in clinical medicine and basic research. With the development of precision medicine, targeted treatment based on the characteristics of DNA mutation and immunotherapy targeting PD-1/PD-L1, CTLA-4 and other pathways have promoted the progress of the overall diagnosis and treatment level of lung cancer, which has been widely used in clinical practice. While making the continuous achievements in the above fields, the researchers committed to lung cancer research are gradually shifting their attention to the exploration of RNA level. Some results have been accumulated in the effects of RNA epigenetic modifications on the biological behavior of lung cancer. N6-methyladenosine(m6A) is the most abundant form of mRNA methylation. The dysfunction of m6A modification mediated by related regulatory proteins has been reported to play an important role in the development and progression of lung cancer. This paper focuses on the detection methods of m6A modification, related regulatory proteins and their mode of action, and reviews the effects on the onset, diagnosis, treatment and prognosis of lung cancer. The aim is not only to summarize the researchers' latest understanding of the epigenetic regulatory mechanism, but also to provide new perspectives for the early diagnosis, effective drug use and prognosis judgment of lung cancer.
